BLTE

Belite Bio

BLTE

Market cap $2.4B

Overview Fund Activity

73.00 USD

+6.10

9.12%

At close Updated Sep 17, 4:00 PM EDT

1 day

9.12%

5 days

9.56%

1 month

12.39%

3 months

24.68%

6 months

7.65%

Year to date

12.72%

1 year

50.45%

5 years

589.33%

10 years

589.33%

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 25

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0% more funds holding

Funds holding: 18 [Q1] → 18 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.22% less ownership

Funds ownership: 0.46% [Q1] → 0.25% (-0.22%) [Q2]

55% less capital invested

Capital invested by funds: $9.91M [Q1] → $4.51M (-$5.4M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$98

34% upside

Avg. target

$98

34% upside

High target

$98

34% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Yi Chen

$98

Buy

Maintained

15 Sep 2025

See Analyst Rankings

Financial journalist opinion

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt disease type 1 (STGD1).

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("Belite Bio" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into securities purchase agreements with leading healthcare investors for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $125 million, before deducting placement agent fees and estimated offering expenses, and up to an additional approximately $150 million in gross proceeds if the accompanying warrants are fully exercised for cash.

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Belite Bio, Inc (NASDAQ:BLTE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Hao-Yuan Chuang - CFO & Director Hendrik P.N. Scholl - Chief Medical Officer Nathan L.

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update.

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Belite Bio Announces Registered Direct Offering of $15 Million

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares (“ADSs”) and warrants to purchase 230,770 ADSs, at a purchase price of $65 per ADS and accompanying warrant, pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses, as well as the potential for additional proceeds of approximately $15 million from the exercise of five-year warrants issued in the offering. The closing of the offering is expected to occur on or about August 8, 2025, subject to the satisfaction of customary closing conditions.

Belite Bio Announces Registered Direct Offering of $15 Million

Zacks Investment Research

New Strong Sell Stocks for August 4th

BBCP, BLTE and CWH have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2025.

New Strong Sell Stocks for August 4th

Zacks Investment Research

New Strong Sell Stocks for July 22nd

BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.

New Strong Sell Stocks for July 22nd

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. There are currently no approved treatments for STGD1.

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is encouraging, but assumptions of success are risky given the small STGD1 market and lack of robust clinical data. Belite's $2bn valuation appears to price in success for both STGD1 and GA, yet GA efficacy data is lacking and competition is fierce.

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

See News Rankings

Charts implemented using Lightweight Charts™